EXHIBIT 99.1

THURSDAY JULY 5, 13:43 EASTERN TIME

PRESS RELEASE

                   BIOPOOL INTERNATIONAL BECOMES XTRANA, INC.

DENVER, Colorado (July 5, 2001) - Xtrana, Inc. (OTCBB:BIPL) today announced that
the Company has changed its name from Biopool  International,  Inc.,  to Xtrana,
Inc. The name change was approved by the  Company's  stockholders  at its Annual
Meeting held June 21, 2001. An Amended and Restated Certificate of Incorporation
of Biopool International, Inc., changing the corporate name to Xtrana, Inc., was
filed pursuant to the General  Corporation Law of the State of Delaware June 22,
2001.
     Effective July 6, 2001, the Company's Common Stock,  which currently trades
on the OTC Bulletin  Board(R)  under the symbol  BIPL,  will trade under the new
trading symbol XTRN.
     Timothy J. Dahltorp,  the Company's  chief  executive  officer,  commented,
"Using the  corporate  name Xtrana is more  conducive  to our  current  business
strategies  and  mission,  and has been  contemplated  since the merger  itself.
Operating under both the Biopool  International  and Xtrana brand names over the
past year has  created  some level of  confusion  in the  marketplace  as to the
Company's identity.  Changing our name to Xtrana, Inc., clearly communicates our
commitment  to the  development  and  commercialization  of  nucleic  acid based
diagnostics.  We will,  however,  leverage off of the  well-established  Biopool
brand name by continuing  to sell our clinical  diagnostic  products  under this
trade name."
     Xtrana, Inc., develops, manufactures, and markets a full range of test kits
to assess and diagnose disorders of blood coagulation,  thrombotic risk factors,
fibrinolysis,  platelet  function,  and the vascular system.  Effective with the
Company's  merger in August 2000, the Company also develops  nucleic  acid-based
tests  for  use  in  drug  discovery,   detection  of  environmental   and  food
contaminants,  forensics,  and  identity  testing,  human and  animal  diseases,
genetic  predisposition to disease, and other applications.  To learn more about
Xtrana, visit the Company's new website at www.xtrana.com.

NOTE: This press release contains  forward-looking  statements,  which are based
upon  current  expectations  that  involve a number  of risks and  uncertainties
including, but not limited to, technological innovations of competitors, changes
in health care regulations,  litigation  claims,  foreign currency  fluctuation,
product  acceptance  or  changes  in  government  regulation  of  the  Company's
products,  as well as other factors  discussed in the  Company's  last Report on
Form 10-KSB under "Risk Factors."


Contact:
     Biopool International Inc./Xtrana
     Timothy Dahltorp, 303/474-2133
     Carol Hill, 805/654-0643

                                       5